Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.
Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.
SafeHeal is a medical technology company focused on developing innovative devices to enhance postoperative care for patients undergoing treatment for colorectal cancer. The company has created a flexible bypass sheath that employs a vacuum-based mechanism, which remains in place until the body's natural healing processes are complete. This device is specifically designed to protect gastrointestinal anastomosis, thereby improving the quality of life for patients during recovery. SafeHeal was established by MD Start, a medtech accelerator, and is backed by funding from MD Start and Sofinnova Partners. The company has received several accolades for its innovation, including recognition in the Worldwide Innovation Challenge and the iLab grant program, as well as being named the most promising MedTech startup at Biovision 2016 and a finalist in the global Medtech Innovator competition. Additionally, SafeHeal was awarded the Charles Foix grant for its contributions to enhancing the quality of life for elderly individuals.
Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.
Home Biosciences is a European venture builder dedicated to biotech.
TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.
Mnemo Therapeutics is a biotechnology firm focused on developing immune-based therapies, particularly cell therapies, aimed at treating solid tumors and blood cancers. The company utilizes its EnfiniT platform, a drug discovery engine that harnesses a unique class of antigens and various technologies to target tumorous epitopes prevalent in multiple cancer types. By leveraging epigenetic variation and CAR-T precision genetic engineering, Mnemo Therapeutics strives to create accessible allogeneic treatments that offer effective solutions for patients facing these challenging diseases.
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.
Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative retinal implant systems to restore vision for individuals who have lost sight due to degeneration of photoreceptor cells in the retina. Established in 2011, Pixium Vision's primary product is the PRIMA System, a bionic vision system designed to improve visual perception and promote greater independence among users. The company is advancing several devices, including the IRIS1, currently undergoing clinical trials, and the next-generation IRIS2, which aims to enhance visual acuity. Additionally, Pixium is working on the IRIS3, a sub-retinal implant that promises further improvements in vision. The company collaborates with prestigious institutions such as Stanford University, Moorfields Eye Hospital, and the Institut de la Vision, utilizing cutting-edge research in neural processing and micro-electronics to drive its innovations. Pixium Vision is supported by a consortium of prominent European venture capital firms.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.
TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.
Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.
Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.
May Health specializes in developing innovative solutions for infertility related to Polycystic Ovary Syndrome (PCOS). The company offers a minimally invasive procedure aimed at restoring ovulation in women with PCOS, providing a more natural approach to pregnancy. This one-time treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure is designed to assist the body's natural ovulation process and can be conducted in a clinical setting, similar to techniques used by fertility specialists in in vitro fertilization (IVF). May Health's focus is on delivering effective, durable solutions for patients seeking to conceive while minimizing the medicalization of the pregnancy experience.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.
SafeHeal is a medical technology company focused on developing innovative devices to enhance postoperative care for patients undergoing treatment for colorectal cancer. The company has created a flexible bypass sheath that employs a vacuum-based mechanism, which remains in place until the body's natural healing processes are complete. This device is specifically designed to protect gastrointestinal anastomosis, thereby improving the quality of life for patients during recovery. SafeHeal was established by MD Start, a medtech accelerator, and is backed by funding from MD Start and Sofinnova Partners. The company has received several accolades for its innovation, including recognition in the Worldwide Innovation Challenge and the iLab grant program, as well as being named the most promising MedTech startup at Biovision 2016 and a finalist in the global Medtech Innovator competition. Additionally, SafeHeal was awarded the Charles Foix grant for its contributions to enhancing the quality of life for elderly individuals.
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.
MD Start is an incubator and fund dedicated to medical technologies. MD Start creates, develops, and operates medical projects, turning them into new companies with both strategic and hands-on approaches, in order to bring them to investment stage and commercial development.
MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways. They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcare community, in order to improve patient care in areas of high unmet medical need. Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction. In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases.
TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.
Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.
Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative retinal implant systems to restore vision for individuals who have lost sight due to degeneration of photoreceptor cells in the retina. Established in 2011, Pixium Vision's primary product is the PRIMA System, a bionic vision system designed to improve visual perception and promote greater independence among users. The company is advancing several devices, including the IRIS1, currently undergoing clinical trials, and the next-generation IRIS2, which aims to enhance visual acuity. Additionally, Pixium is working on the IRIS3, a sub-retinal implant that promises further improvements in vision. The company collaborates with prestigious institutions such as Stanford University, Moorfields Eye Hospital, and the Institut de la Vision, utilizing cutting-edge research in neural processing and micro-electronics to drive its innovations. Pixium Vision is supported by a consortium of prominent European venture capital firms.
MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways. They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcare community, in order to improve patient care in areas of high unmet medical need. Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction. In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases.
Sensitive Object SA specializes in the development of electronic products that enhance touch interface technology across various sectors. Founded in 2003 and headquartered in Boulogne Billancourt, France, the company offers solutions for consumer electronics, computing, outdoor interactive applications, home automation, healthcare, industrial control, and digital advertising. Its product range includes touch screens, peripherals, and control panels, catering to diverse industry needs. Sensitive Object also maintains operations in Paris and Singapore, further expanding its reach in the global market.
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.
Qosmos SA is a provider of network intelligence technology that specializes in deep packet inspection (DPI) for IP traffic classification and analysis. Founded in 2000 and based in Paris, the company develops software and hardware platforms designed to identify and extract information traveling through networks. Its flagship product, ixEngine, includes a comprehensive software development kit offering tools for traffic analysis, protocol recognition, and real-time classification of data flows. Qosmos' solutions support various applications, including lawful interception, network protection, data retention, regulatory compliance, and content-based billing. The company also offers custom development services and professional consulting to assist with the design, deployment, and optimization of network intelligence systems. With additional offices in London, Silicon Valley, Tokyo, and Singapore, Qosmos operates globally and has been a subsidiary of Enea AB since 2016.
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.
Stentys S.A. is a medical device company focused on designing, developing, and marketing self-expanding stents for the treatment of cardiovascular diseases, particularly in cases of acute myocardial infarction and other complex coronary conditions. The company offers a range of products, including xpositions, mistent, stentys btk, stentys ac, and stentys stent. Stentys operates in various regions, including Europe, the Middle East, Asia, and Latin America, aiming to provide innovative solutions to enhance patient outcomes in cardiovascular care.
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.
Stentys S.A. is a medical device company focused on designing, developing, and marketing self-expanding stents for the treatment of cardiovascular diseases, particularly in cases of acute myocardial infarction and other complex coronary conditions. The company offers a range of products, including xpositions, mistent, stentys btk, stentys ac, and stentys stent. Stentys operates in various regions, including Europe, the Middle East, Asia, and Latin America, aiming to provide innovative solutions to enhance patient outcomes in cardiovascular care.
Qosmos SA is a provider of network intelligence technology that specializes in deep packet inspection (DPI) for IP traffic classification and analysis. Founded in 2000 and based in Paris, the company develops software and hardware platforms designed to identify and extract information traveling through networks. Its flagship product, ixEngine, includes a comprehensive software development kit offering tools for traffic analysis, protocol recognition, and real-time classification of data flows. Qosmos' solutions support various applications, including lawful interception, network protection, data retention, regulatory compliance, and content-based billing. The company also offers custom development services and professional consulting to assist with the design, deployment, and optimization of network intelligence systems. With additional offices in London, Silicon Valley, Tokyo, and Singapore, Qosmos operates globally and has been a subsidiary of Enea AB since 2016.
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.
Sensitive Object SA specializes in the development of electronic products that enhance touch interface technology across various sectors. Founded in 2003 and headquartered in Boulogne Billancourt, France, the company offers solutions for consumer electronics, computing, outdoor interactive applications, home automation, healthcare, industrial control, and digital advertising. Its product range includes touch screens, peripherals, and control panels, catering to diverse industry needs. Sensitive Object also maintains operations in Paris and Singapore, further expanding its reach in the global market.
InfraWorlds is an innovative French startup specializing in embedded Java technologies and solutions for wireless phones. Its technological competencies, coupled with unrivalled graphic creativity, have earned the company a solid reputation among the main players in this booming sector. Built around a team of dedicated professionals, which is soon to be expanded, InfraWorlds is today consolidating its lead in the fast-growing global wireless entertainment market.